A PYMNTS Company

US: FTC orders concessions on $1.6B generic drugmaker buyout

 |  September 29, 2013

The US Federal Trade Commission announced its approval for generic drugmaker giant Mylan to acquire Agila in a $1.6 billion deal, though the regulator will require Mylan to divest assets that make 11 drugs to quell competition concerns.

According to reports, Mylan is set to buy the India-based unit of Strides Arcolab as the US conglomerate looks to double its injectable drugs portfolio.

The deal was first announced last February.

Full Content: Economic Times of India

Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.